Department of Cardiothoracic and Vascular Surgery, Careggi University Teaching Hospital, University of Florence, Florence, Italy.
Department of Cardiothoracic and Vascular Surgery, Careggi University Teaching Hospital, University of Florence, Florence, Italy.
Ann Vasc Surg. 2023 Jul;93:92-102. doi: 10.1016/j.avsg.2023.02.038. Epub 2023 Mar 9.
To retrospectively evaluate the feasibility and effectiveness of the endovascular treatment of patients with abdominal aortic aneurysm and chronic kidney disease (CKD) without the need for using iodinated contrast media throughout the diagnostic, therapeutic, and follow-up pathway.
A retrospective review of prospectively collected data concerning 251 consecutive patients presenting an abdominal aortic or aorto-iliac aneurysm who underwent endovascular aneurysm repair (EVAR) from January 2019 to November 2022 at our academic institution was performed in order to identify patients with feasible anatomy with respect to manufacturer's instructions for use and with CKD. Patients whose preoperative workout included duplex ultrasound and plain computed tomography for preprocedural planning were extracted from a dedicated EVAR database. EVAR was performed with the use of carbon dioxide (CO) as the contrast media of choice, whereas follow-up examinations consisted of either duplex ultrasound, plain computed tomography, or contrast-enhanced ultrasound. Primary endpoints were technical success, perioperative mortality, and early renal function variations. Secondary endpoints were all-type endoleaks and reinterventions, midterm aneurysm-related and kidney-related mortality.
Forty-five patients had CKD and were treated electively (45/251, 17.9%). Of them, 17 patients were managed with a total iodinated contrast media-free strategy and constituted the object of the present study (17/45, 37.8%; 17/251, 6.8%). In 7 cases, an adjunctive planned procedure was performed (7/17, 41.2%). No intraoperative bail-out procedures were needed. This extracted cohort of patients presented similar mean preoperative and postoperative (at discharge) glomerular filtration rate values, 28.14 (SD 13.09; median 28.06, interquartile range (IQR) 20.25) ml/min/1.73 m and 29.33 (SD 14.61; median 27.35, IQR 22) ml/min/1.73 m, respectively (P = 0.210). Mean follow-up was 16.4 months (SD 11.89; median 18, IQR 23). During follow-up, no graft-related complications occurred in terms of either thrombosis, type I or III endoleaks, aneurysm rupture, or conversion. The mean glomerular filtration rate at follow-up was 30.39 ml/min/1.73 m (SD 14.45; median 30.75, IQR 21.93), with no significant worsening in comparison with preoperative and postoperative values (P = 0.327 and P = 0.856 respectively). No aneurysm- or kidney-related deaths occurred during follow-up.
Our initial experience shows that total iodine contrast-free abdominal aortic aneurysm endovascular management in patients with CKD may be feasible and safe. Such an approach seems to guarantee the preservation of residual kidney function without increasing the risks of aneurysm-related complications in the early and midterm postoperative periods, and it could be considered even in the case of complex endovascular procedures.
回顾性评估在诊断、治疗和随访过程中无需使用含碘对比剂对患有慢性肾脏病(CKD)的腹主动脉瘤患者进行血管内治疗的可行性和有效性。
对 2019 年 1 月至 2022 年 11 月期间在我院行血管内修复术(EVAR)的 251 例连续就诊的腹主动脉瘤或腹主动脉髂动脉瘤患者的前瞻性收集数据进行回顾性分析,以确定符合制造商使用说明的可行解剖结构,并伴有 CKD。从专门的 EVAR 数据库中提取术前包括双功能超声和 CT 平扫用于术前规划的患者。EVAR 采用二氧化碳(CO)作为首选对比剂,而随访检查包括双功能超声、CT 平扫或对比增强超声。主要终点是技术成功率、围手术期死亡率和早期肾功能变化。次要终点是所有类型的内漏和再干预、中期动脉瘤相关和肾脏相关死亡率。
45 例 CKD 患者接受了择期治疗(45/251,17.9%)。其中,17 例患者采用了完全不含碘对比剂的策略,这是本研究的对象(17/45,37.8%;17/251,6.8%)。在 7 例中,进行了附加的计划手术(7/17,41.2%)。术中无需抢救性程序。这一提取队列的患者术前和术后(出院时)肾小球滤过率相似,分别为 28.14(SD 13.09;中位数 28.06,四分位距(IQR)20.25)ml/min/1.73m 和 29.33(SD 14.61;中位数 27.35,IQR 22)ml/min/1.73m(P=0.210)。平均随访时间为 16.4 个月(SD 11.89;中位数 18,IQR 23)。随访期间,无移植物相关并发症,包括血栓形成、I 型或 III 型内漏、动脉瘤破裂或转换。术后肾小球滤过率平均值为 30.39ml/min/1.73m(SD 14.45;中位数 30.75,IQR 21.93),与术前和术后相比无明显恶化(P=0.327 和 P=0.856)。随访期间无动脉瘤或肾脏相关死亡。
我们的初步经验表明,在 CKD 患者中进行完全不含碘的腹主动脉瘤血管内管理可能是可行和安全的。这种方法似乎可以保证保留残余肾功能,而不会增加早期和中期术后动脉瘤相关并发症的风险,即使在复杂的血管内手术中也可以考虑。